[2] It is important to be precise here
Wegovy and Saxenda are for adults diagnosed with obesity a body mass index (BMI) of 30 or higher or those with a BMI of 27 plus at least one weight-related condition, like high blood pressure, high cholesterol, or type 2 diabetes
Unlike GHRP-6 and GHRP-2, ipamorelin does not elevate plasma cortisol or ACTH at growth hormone-releasing doses
Negli ultimi anni luso degli agonisti del recettore GLP-1 come il semaglutide (noto con i nomi commerciali Ozempic e Wegovy ), ha registrato un forte aumento
In 2026, CMS announced a GLP-1 payment demonstration and the BALANCE model aimed at expanding access and lowering costs, with published materials referencing beneficiary out-of-pocket costs under $50/month for eligible participants though the actual numbers depend on participation and program eligibility rules that are still being finalized
In October 2025, the Welsh government confirmed plans to develop a new clinical pathway to treat obesity as a chronic, recurring condition and support equitable access to weight-loss drugs and wrap-around care, including in appropriate primary care and community settings 42